EU Approval for Targeting High-Risk AML

The European Union approved Vyxeos Liposomal (daunorubicin and cytarabine) on August 23, 2018, for adult patients with newly diagnosed treatment-related acute myeloid leukemia (t-AML) and acute myeloid leukemia with myelodysplasia-related changes (AML-MRC). The Committee for Medicinal Products for Human Use (CHMP) under the European Medicines Agency (EMA) adopted a positive opinion on April 26, 2018, and the European Commission subsequently granted a marketing authorization valid throughout the EU member states. The marketing authorization holder is Jazz Pharmaceuticals Ireland Limited, and the parent company, Jazz Pharmaceuticals plc (JAZZ), is responsible for the development and commercialization. The clinical stage is Marketed, and the approval specifically targets poor-prognosis secondary AML rather than broad AML.

Differentiation of Fixed-Ratio Liposome CPX-351

Vyxeos, with the generic name daunorubicin and cytarabine liposome injection, has the development code CPX-351. Daunorubicin is an anthracycline topoisomerase II inhibitor, and cytarabine is a nucleoside metabolic antagonist that inhibits DNA synthesis. The two components are encapsulated in a 1:5 molar ratio of daunorubicin to cytarabine to maintain a synergistic ratio in the bloodstream and bone marrow. Therefore, while using the same components as the conventional 7+3 regimen, the drug exposure and delivery method have been differentiated as product features.

Phase 3 Survival Data Drives Approval

The randomized, open-label Phase 3 CLTR0310-301 study, registered as NCT01696084, enrolled 309 patients aged 60-75 with newly diagnosed high-risk/secondary AML and randomized them 1:1 to receive Vyxeos or standard 7+3 therapy. The median overall survival was 9.56 months versus 5.95 months, with a hazard ratio of 0.69, a 95% confidence interval of 0.52 to 0.90, and a two-sided p-value of 0.005. The one-year survival rate was also 41.5% versus 27.6%, demonstrating that the reformulation of the same cytotoxic components into a fixed-ratio liposome formulation resulted in a clinically meaningful survival benefit. The FDA approved the adult indication on August 3, 2017, following a non-AdComm approval process, and expanded it to include patients aged 1 year and older on March 30, 2021. Japan approved it on March 26, 2024.

Market Maturity and Treatment Differentiation

The global AML treatment market is valued at $3.91 billion in 2025, but the direct demand for Vyxeos is focused on patients with t-AML and AML-MRC who can undergo intensive induction therapy. The direct comparison is with the daunorubicin and cytarabine 7+3 regimen, and for elderly or patients unsuitable for intensive therapy, the combination of Venclexta (venetoclax, a BCL-2 inhibitor) and azacitidine from AbbVie (ABBV) and Genentech is the standard of care. Vyxeos' net sales decreased by 10.2% from $162.59 million in 2024 to $146.03 million in 2025, reflecting the maturity of the approved asset and patient segmentation. The key variables for growth in Europe are country-specific reimbursement access, adoption rates in transplant centers, and the selection of patients suitable for intensive therapy.